Volume 103, Issue 1 pp. 102-103

Carvedilol Overdose with Quantitative Confirmation

Nicole C. Bouchard

Nicole C. Bouchard

New York City Poison Control Center, New York, NY, USA,

Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, NY, USA, and

Search for more papers by this author
Jenice Forde

Jenice Forde

Columbia University Medical Center/NewYork-Presbyterian Hospital, New York, NY, USA, and

Search for more papers by this author
Robert S. Hoffman

Robert S. Hoffman

New York City Poison Control Center, New York, NY, USA,

New York University Medical Center, New York, NY, USA

Search for more papers by this author
First published: 28 June 2008
Citations: 14
Author for correspondence: Nicole C. Bouchard, 622 W 168th Street PH 1-137, New York, NY 10032, USA (fax +1 (212) 305 6792, e-mail [email protected]).

Abstract

Abstract: Carvedilol is a non-selective β-adrenoreceptor antagonist that is also an antagonist at the α1-adrenoreceptor. This unique pharmacological effect may produce a different toxicodynamic profile compared to other β-adrenoreceptor antagonists. Only one previous case of carvedilol overdose has been reported. Here, we report massive carvedilol ingestion confirmed by quantitative analysis. The case report deals with an 84-year-old man who chewed a total of 60 (6.25 mg) tablets and rapidly developed symptoms. Vital signs on presentation were systolic blood pressure 70 mmHg; heart rate 45 beats/min.; respirations 18 breaths/min.; temperature 37°. The electrocardiogram showed a junctional rhythm at 49 beats/min. The patient was treated with normal saline boluses, repeated glucagon boluses (2–3 mg each) and a dopamine infusion. At 14 hr after ingestion, he was weaned off vasopressors and was in a normal sinus rhythm. Quantitative confirmation showed a carvedilol serum concentration of 472 ng/ml (steady-state concentration 8.5 ng/ml during 6.25 mg twice daily dosing). Despite its unique pharmacological properties, the clinical manifestations of carvedilol overdose appear similar to other β-adrenoreceptor antagonists.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.